Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 33.95M 24.36M 21.07M 19.68M 18.05M 2.32B 34.49M 231M 90.61M 1.16B 91.47M 89.47M 3.84B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 33.72M 24.19M 20.93M 19.54M 17.93M 2.3B 34.26M 229M 90M 1.15B 90.85M 88.87M 3.82B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
1 day+17.19%
1 week+17.19%
Current month+17.19%
1 month+12.50%
3 months+50.00%
6 months+2.27%
Current year-13.53%
1 week 0.1
Extreme 0.096
0.11
1 month 0.1
Extreme 0.096
0.11
Current year 0.01
Extreme 0.014
0.2
1 year 0
Extreme 0.0033
0.2
3 years 0
Extreme 0.0005
0.25
5 years 0
Extreme 0.0005
0.25
10 years 0
Extreme 0.0005
0.25
Manager TitleAgeSince
Chief Executive Officer - 01/07/2019
Director of Finance/CFO - 17/08/2022
Chief Tech/Sci/R&D Officer - 17/09/2024
Director TitleAgeSince
Director/Board Member - 06/12/2017
Director/Board Member - 01/07/2019
Chairman - 30/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
+17.19%+17.19% - - 24.19M
-0.52%+3.21%+85.02%+161.12% 1,062B
+0.88%+1.13%+51.13%+49.76% 619B
+0.89%-1.95%+23.73%+63.67% 431B
+0.71%+3.93%+47.75%+38.58% 358B
+0.64%-0.63%+36.39%+41.44% 293B
+0.39%-6.48%+7.62%+9.04% 247B
+1.51%+6.69%+44.34%+62.47% 219B
+3.92%-7.80%+5.39%-42.52% 200B
+1.80%+2.30%+20.79%+65.13% 162B
Average +2.77%-1.90%+35.79%+49.85% 399.14B
Weighted average by Cap. +0.66%-0.83%+49.00%+76.10%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.4 0.03 0.03 1.32
Net income -1.71M -1.22M -1.06M -989K -908K -117M -1.73M -11.61M -4.56M -58.43M -4.6M -4.5M -193M -3.53M -2.53M -2.19M -2.05M -1.88M -241M -3.59M -24.02M -9.43M -121M -9.52M -9.31M -400M
Net Debt -113K -80.81K -69.9K -65.28K -59.88K -7.69M -114K -766K -301K -3.85M -303K -297K -12.74M -231K -165K -143K -134K -123K -15.74M -234K -1.57M -615K -7.89M -621K -608K -26.09M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
08/08/26 US$0.1125 +17.19% 6,500
05/08/26 US$0.0960 -4.00% 7,500
04/08/26 US$0.1000 +4.17% 20,000
31/07/26 US$0.0960 -2.04% 10,000

Annual profits - Rate of surprise